Lumibird SA
Runyon, October 15, 2024 – 17:45 p.m.
LumiBird: Bank renews confidence in group strategy with funding of over 100 million euros
55.2 million can be repaid over 7 years to reschedule existing loan
Plans to raise $50 million in acquisition funds over three years
LUMIBIRD Group (FR0000038242 – LBIRD), the European leader in laser technology, has rescheduled its current borrowings, taking into account, inter alia, the maturities of its corporate bond obligations, and has banked more than 100 million euros to finance potential acquisitions. announced that the financing had been completed. chance.
The financing round was financed by Crédit Agricole Côtes d’Armor (lead bank), Arcéa Banque Entreprise et Institutionnelle, Banque Populaire Grand Ouest, Vault de Bretagne Pays de Loire and LCL. configured. All these banks are part of Lumibard’s historic banking pool. Through this funding, we are renewing our confidence in the Group’s strategy.
This funding consists of two lines.
55.2 million repayable over 7 years due to the rescheduling of existing borrowings, particularly taking into account the maturity of the bond debt.
The EUR 50 million* can be withdrawn over three years, with 40% repaid at maturity and the remainder amortized over a total of seven years.
The applicable rate spread is the same as the previous round in December 2020.
Marc Le Frohic, Chairman and CEO of LumiBird, said: “The renewed confidence shown by our bank partners is a powerful opportunity for us at a time when LumiBird needs to demonstrate its ability to drive profitability. It’s a sign.”
*Line not confirmed
Next date: Q3 2024 earnings, after close October 21, 2024
LUMIBIRD is one of the world’s leading laser companies. With 50 years of experience and expertise in solid-state, diode and fiber laser technologies, the group designs, manufactures and markets high-performance laser solutions through two divisions: Photonics and Medical. The Photonics segment designs and manufactures components, lasers, and systems for the defense and space, environmental, terrain and safety, industrial and scientific, and medical technology markets. The Medical Division designs and manufactures medical diagnostic and treatment systems for ophthalmology.
As a result of the merger of the Keopsys Group and the Quantel Group in October 2017, LUMIBIRD has more than 1,000 employees, a turnover of more than 203.6 million euros in 2023, and a presence in Europe, the Americas and Asia.
LUMIBIRD shares are listed in Compartment B of Euronext Paris. FR0000038242 – LBIRD www.lumibird.com
LUMIBIRD is a member of Euronext Tech Leaders from 2022.
contact address
lumibird
marc le frohic
Chairman and CEO
Phone number +33(0) 1 69 29 17 00
info@lumibird.com
lumibird
Sonia Rutnam
Chief Financial and Transformation Officer
Phone number +33(0) 1 69 29 17 00
info@lumibird.com
Calyptus
Mathieu Carew
Investor information
Phone number +33(0) 1 53 65 37 91
lumibird@calyptus.net
attachment